JERUSALEM, January 24, 2011 /PRNewswire-FirstCall/ -- Medisafe 1 Technologies Corp. (OTCBB: MFTH), a developer of patented technologies that physically prevent unauthorized administration of prescription medications, announced today that the company expects revenues in 2012 to exceed $10M .

Revenues will be derived from the licensing of Medisafe 1 Technology's patented locking devices on syringes and the licensing of the related Bar-Code Pre-Matching safety device software application .The patent is also applicable to intravenous infusion and transfusion bags.

Discussions for licensing the technology devices are already underway in Israel, where the technology is expected to eventually be implemented across the State's nationwide medical system.

Medisafe 1 Technologies is currently attempting to enter into additional markets for its lifesaving technologies.

"Many reputable organizations and companies have expressed the value they recognize in our technologies," said, Jacob Elhadad, CEO of Medisafe 1 Technologies. "Through the further development of existing marketing channels, and the mass production of our licensed products, we expect reporting revenues in 2012 to exceed $10 million."

About Medisafe 1 Technologies

Medisafe 1 Technologies seeks to effectively prevent unauthorized administration of a drug or medicinal substance by hypodermic needle. Medisafe's patented technology is a medical assembly with a locking mechanism that is intended to ensure the substance cannot be released from the hypodermic needle without positive pre-matching between the substance and its intended patient.

Forward-Looking Statements

This letter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities Exchange Act of 1934 as amended. All forward-looking statements are inherently uncertain, based on current expectations and assumptions concerning future events or future performance of Medisafe 1 Technologies Corp., and its technologies. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release, as actual results may differ materially from those indicated. Medisafe 1 Technologies Corp. public filings may be viewed at http://www.sec.gov.



    Contact:

    Jacob Elhadad
    CEO
    +972-524440000
    Jacob.elhadad10@gmail.com

SOURCE Medisafe 1 Technologies Corp.